Advertisement
Canada markets open in 5 hours 42 minutes

  • S&P/TSX

    22,290.62
    +31.15 (+0.14%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • DOW

    38,884.26
    +31.99 (+0.08%)
     

  • CAD/USD

    0.7272
    -0.0015 (-0.21%)
     

  • CRUDE OIL

    77.65
    -0.73 (-0.93%)
     

  • Bitcoin CAD

    85,661.73
    -1,894.23 (-2.16%)
     

  • CMC Crypto 200

    1,288.98
    -5.69 (-0.44%)
     

  • GOLD FUTURES

    2,319.30
    -4.90 (-0.21%)
     

  • RUSSELL 2000

    2,064.65
    +3.97 (+0.19%)
     

  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     

  • NASDAQ futures

    18,207.25
    +7.75 (+0.04%)
     

  • VOLATILITY

    13.22
    -0.01 (-0.08%)
     

  • FTSE

    8,351.61
    +37.94 (+0.46%)
     

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • CAD/EUR

    0.6767
    -0.0004 (-0.06%)
     

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines, Inc.
·2 min read
Revolution Medicines, Inc.
Revolution Medicines, Inc.

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.

Details of the company’s participation are as follows:

  • 23rd Annual Needham Healthcare Conference
    Conference Dates: April 8-11, 2024
    Fireside Chat Time/Date: 1:30 – 2:10 p.m. ET on Thursday, April 11, 2024
    Location: Virtual; webcast available

ADVERTISEMENT

  • Stifel Targeted Oncology Forum
    Conference Dates: April 16-17, 2024
    Fireside Chat Time/Date: 3:30 – 3:55 p.m. ET on Tuesday, April 16, 2024
    Location: Virtual; webcast available

To access the live webcasts of the Needham and Stifel fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

CONTACT: Media & Investor Contact Erin Graves 650-779-0136 egraves@revmed.com